Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI5884 in healthy volunteers
NCT03001297Phase 1Completed
- Sponsor
- MedImmune
- Start
- Jan 2017
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MEDI5884 in cardiovascular disease (CVD) (5 arms), sponsored by MedImmune. Primary endpoints: Number of subjects with adverse events up to 90 days and HDL-Cholesterol over time up to 90 days. Started Jan 2017; status: completed.
02
Drugs
MEDI5884
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT03001297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03001297.